Ocular myasthenia gravis is an autoimmune condition affecting the muscles surrounding and involving the eyes. Symptoms can include double vision, droopy eyelids, and more. Ocular myasthenia gravis ...

Five therapies are currently approved by the FDA for treating the symptoms of myasthenia gravis, allowing partial to complete remission. Research suggests that five new therapies may become available ...

Doctors may recommend oral medications such as pyridostigmine and various intravenous (IV) drugs for the treatment of myasthenia gravis. Thymectomy surgery and plasma exchange may also help. The aim ...

Myasthenia gravis is becoming increasingly common around the world, with a resulting disease burden beset by high health care resource utilization, decreased quality of life, and worsened mental ...

Regular low to moderate intensity exercise is usually safe with myasthenia gravis. Exercise may not clearly reduce myasthenia gravis symptoms, but it can improve strength, balance, mobility, endurance ...

Francisco J. Rivera Rosario is a science communications editor experienced in developing all types of science content including, scientific journal articles, infographics, medical educational videos, ...

Albert Stowell's family thought he was having a stroke. It was Easter dinner 2014, and they were all gathered around the table when he started slurring his words. A trip to the emergency room and a CT ...

Diagnosis of generalized myasthenia gravis involves clinical symptoms, serologic markers, and electrodiagnostic studies, with AChR and MuSK autoantibodies being key indicators. Differentiating ...

Myasthenia gravis is a lifelong (chronic) autoimmune condition, which means that the body’s immune system attacks its own healthy cells. Most people with generalized myasthenia gravis (gMG) have ...

Former tennis star Monica Seles recently revealed she is living with the rare disease myasthenia gravis, which affects 12 in 100,000 people globally. Subscribe to our newsletter for the latest ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...